The Biostatistics Core provides statistical collaboration and/or data management for each of the SPORE projects, the Developmental Research Program projects, the Career Development Program projects, and the other Cores. Each project In this application has received input from the Biostatistics Core on study design and analysis plans. The statistical needs of the projects span a range of approaches and analyses;the projects range from pre-clinical studies to clinical trials. The Biostatistics Core builds upon the innovative, time-tested procedures and systems developed by one of the largest statistical groups in the country, which has successfully collaborated on more than 13,000 clinical and basic research studies since 1966. The Biostatistics core will provide each investigator access to statistical expertise: collaborative development of study designs, data collection tools, analysis plans, state of the art statistical modeling, analysis and interpretation of high-dimensional data, data management activities, and abstract/presentation/publication preparation. Members of the core have experience in the management and integration of existing and newly collected data that ensures consistent and compatible data handling. This Core complements and assists the efforts of the Animal Core, Clinical Research Core, and the Pathology and Tissue Procurement Core. The strengths of the Biostatistics Core includes our collaborative relationship with the projects'and cores' investigators, our knowledge of and ability to utilize the established research databases, our access to the operational and statistical infrastructure already in place in the institution, and the combined expertise and experience of our personnel.

Public Health Relevance

The Biostatistics Core is essential for the design, analysis, and unambiguous display of SPORE-generated data. The Core provides oversight of all SPORE related statistical activities, which allows synergies and efficiencies for systemic and programmatic initiatives beyond what can be achieved with individual statistical teams for each project.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Geekiyanage, Hirosha; Galanis, Evanthia (2016) MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol 10:1387-1403
Rajani, Karishma; Parrish, Christopher; Kottke, Timothy et al. (2016) Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther 24:166-74
Ma, Yufang; Tang, Nan; Thompson, Reid C et al. (2016) InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res 22:1767-76
Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2016) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol :
Vaubel, Rachael A; Chen, Selby G; Raleigh, David R et al. (2016) Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. J Neuropathol Exp Neurol 75:44-52
Kurokawa, C; Geekiyanage, H; Allen, C et al. (2016) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol :
Zhang, Haoxing; Liu, Hailong; Chen, Yali et al. (2016) A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun 7:10201
Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther 15:1332-43
Kitange, Gaspar J; Mladek, Ann C; Schroeder, Mark A et al. (2016) Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep 14:2587-98
Cockle, Julia V; Rajani, Karishma; Zaidi, Shane et al. (2016) Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 18:518-27

Showing the most recent 10 out of 220 publications